CA2184200A1 - Virus recombinants, preparation et utlisation en therapie genique - Google Patents

Virus recombinants, preparation et utlisation en therapie genique

Info

Publication number
CA2184200A1
CA2184200A1 CA002184200A CA2184200A CA2184200A1 CA 2184200 A1 CA2184200 A1 CA 2184200A1 CA 002184200 A CA002184200 A CA 002184200A CA 2184200 A CA2184200 A CA 2184200A CA 2184200 A1 CA2184200 A1 CA 2184200A1
Authority
CA
Canada
Prior art keywords
bdnf
adenovirus
sequence
cell
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002184200A
Other languages
English (en)
French (fr)
Inventor
Pascal Barneoud
Pia Delaere
Michel Perricaudet
Laurent Pradier
Emmanuelle Vigne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2184200A1 publication Critical patent/CA2184200A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002184200A 1994-03-18 1995-03-02 Virus recombinants, preparation et utlisation en therapie genique Abandoned CA2184200A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR94/03191 1994-03-18
FR9403191A FR2717496B1 (fr) 1994-03-18 1994-03-18 Virus recombinants, préparation et utilisation en thérapie génique.

Publications (1)

Publication Number Publication Date
CA2184200A1 true CA2184200A1 (fr) 1995-09-28

Family

ID=9461190

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002184200A Abandoned CA2184200A1 (fr) 1994-03-18 1995-03-02 Virus recombinants, preparation et utlisation en therapie genique

Country Status (12)

Country Link
EP (1) EP0750676A1 (fi)
JP (1) JPH09510358A (fi)
KR (1) KR970701784A (fi)
AU (1) AU703793B2 (fi)
CA (1) CA2184200A1 (fi)
FI (1) FI963674A0 (fi)
FR (1) FR2717496B1 (fi)
IL (1) IL112992A0 (fi)
MX (1) MX9603490A (fi)
NO (1) NO963559L (fi)
WO (1) WO1995025804A1 (fi)
ZA (1) ZA952244B (fi)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830857A (en) * 1995-07-14 1998-11-03 Amgen Inc. Method of treating epilepsy
FR2753379B1 (fr) * 1996-09-13 1998-10-30 Rhone Poulenc Rorer Sa Methode de traitement de la sclerose laterale amyotrophique
ES2322332T3 (es) * 2000-05-05 2009-06-19 The Research Foundation Of The City University Of New York Composiciones para estimular la regeneracion del sistema nervioso y reparacion mediante la regulacion de la sintesis de poliamidas y arginasa 1.
EP3755380A4 (en) * 2018-02-20 2021-12-08 Carmel-Haifa University Economic Corporation Ltd. COMPOSITIONS AND PROCEDURES FOR THE ADMINISTRATION AND EXPRESSION OF SMALL PEPTIDES INHIBITORS AND THEIR USE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT70275A (en) * 1991-07-10 1995-09-28 Regeneron Pharma Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules
WO1993008828A1 (en) * 1991-11-08 1993-05-13 Syntex-Synergen Neuroscience Joint Venture Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1994003199A1 (en) * 1992-08-04 1994-02-17 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
WO1994008026A1 (en) * 1992-09-25 1994-04-14 Rhone-Poulenc Rorer S.A. Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
FR2704234B1 (fr) * 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.

Also Published As

Publication number Publication date
IL112992A0 (en) 1995-06-29
FR2717496B1 (fr) 1996-04-12
KR970701784A (ko) 1997-04-12
AU1896295A (en) 1995-10-09
JPH09510358A (ja) 1997-10-21
FI963674A (fi) 1996-09-17
NO963559L (no) 1996-08-26
WO1995025804A1 (fr) 1995-09-28
FR2717496A1 (fr) 1995-09-22
EP0750676A1 (fr) 1997-01-02
AU703793B2 (en) 1999-04-01
ZA952244B (en) 1996-01-16
FI963674A0 (fi) 1996-09-17
MX9603490A (es) 1997-03-29

Similar Documents

Publication Publication Date Title
EP0752004B1 (fr) Adenovirus recombinants codant pour le facteur neurotrophique des cellules gliales (gdnf)
CA2197235C (fr) Adenovirus comprenant un gene codant pour la glutathion peroxydase
FR2732357A1 (fr) Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose
WO1995026409A1 (fr) ADENOVIRUS RECOMBINANTS CODANT POUR LES FACTEURS DE CROISSANCE DES FIBROBLASTES BASIQUES (bFGF)
CA2190883A1 (fr) Adenovirus comprenant un gene codant pour une superoxyde dismutase
FR2734568A1 (fr) Nouveaux variants de l'apolipoproteine
EP1187919A2 (fr) Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
FR2717495A1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
CA2184200A1 (fr) Virus recombinants, preparation et utlisation en therapie genique
EP0752003B1 (fr) Virus recombinants codant pour une activite glutamate decarboxylase (gad)
FR2753379A1 (fr) Methode de traitement de la sclerose laterale amyotrophique
EP0969885A1 (fr) Procede de stimulation de la regeneration nerveuse
US20020031493A1 (en) Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf)
EP1100946A1 (fr) Vecteurs derives de baculorivus et utilisation pour le transfert d'acides nucleiques dans les cellules nerveuses des vertebres
EP0750674A1 (fr) ADENOVIRUS RECOMBINANTS POUR LE FACTEUR DE MATURATION DES CELLULES GLIALES DE TYPE BETA (GMF-$g(b))
FR2717823A1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2726575A1 (fr) Virus recombinants, preparation et utilisation en therapie genique
FR2793142A1 (fr) Utilisation d'oligonucleotides antisens de no-synthase inductible dans la prevention et le traitement de l'ischemie cerebrale

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued